Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SURGALIGN HOLDINGS, INC.

(SRGA)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
2.090 USD   -1.42%
2022Surgalign Holdings, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
2022HC Wainwright Initiates Surgalign With Buy Rating, Price Target is $3.50
MT
2022Surgalign Announces 100th Case Completed Utilizing its Recently Launched Cortera Spinal Fixation System
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/24/2023 01/25/2023 01/26/2023 01/27/2023 01/30/2023 Date
2.08(c) 2.11(c) 2.04(c) 2.12(c) 2.09 Last
64 440 40 228 65 469 79 390 17 470 Volume
-12.24% +1.44% -3.32% +3.92% -1.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 82,1 M - -
Net income 2022 -29,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,51x
Yield 2022 -
Sales 2023 83,8 M - -
Net income 2023 -40,9 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,45x
Yield 2023 -
Capitalization 26,7 M 26,7 M -
Capi. / Sales 2022 0,32x
Capi. / Sales 2023 0,32x
Nbr of Employees 231
Free-Float 77,7%
More Financials
Company
Surgalign Holdings, Inc. is a medical technology company. The Company is focused on developing an augmented reality (AR) and artificial intelligence (AI) digital surgery platform called HOLO AI, which is an artificial intelligence technology being applied to surgery. The technology is designed to automatically segment and identify detailed patient spine anatomy, autonomously create a surgical plan for surgeon... 
More about the company
Ratings of Surgalign Holdings, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about SURGALIGN HOLDINGS, INC.
2022Surgalign Holdings, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
AQ
2022HC Wainwright Initiates Surgalign With Buy Rating, Price Target is $3.50
MT
2022Surgalign Announces 100th Case Completed Utilizing its Recently Launched Cortera Spinal..
AQ
2022Surgalign Announces 100th Case CompletedáUtilizing its Recently Launched Cortera™..
GL
2022Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched..
CI
2022Surgalign Expands Adoption of its HOLO Portal Surgical Guidance System in Virginia
AQ
2022Surgalign™ Expands Adoption of its HOLO Portal™ Surgical Guidance System in..
GL
2022Surgalign Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-M..
GL
2022Surgalign Holdings, Inc. : Entry into a Material Definitive Agreement, Financial Statement..
AQ
2022Surgalign Announces $12.0 Million Registered Direct Offering Priced At-the-Market Under..
AQ
2022Surgalign Says Board Approves Corporate Restructuring Plan to Drive Growth
MT
2022Surgalign : Costs Associated with Exit/Disposal - Form 8-K
PU
2022Surgalign Holdings, Inc. : Costs Associated with Exit or Disposal Activities (form 8-K)
AQ
2022Surgalign™ Announces Corporate Restructuring Program to Focus on Key Growth Areas
GL
2022Surgalign : Q3 Earnings Snapshot
AQ
More news
News in other languages on SURGALIGN HOLDINGS, INC.
2022Surgalign Holdings, Inc. annonce le 100e cas réalisé à l'aide de son système de fixatio..
2022Surgalign déclare que le conseil d'administration approuve le plan de restructuration d..
2022Surgalign Holdings, Inc. annonce ses résultats pour le troisième trimestre et les neuf ..
2022Surgalign Holdings, Inc. Réduit ses prévisions de revenus pour 2022
2022Surgalign Holdings, Inc. lance son portefeuille de produits Fortilink« avec la technolo..
More news
Analyst Recommendations on SURGALIGN HOLDINGS, INC.
More recommendations
Chart SURGALIGN HOLDINGS, INC.
Duration : Period :
Surgalign Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SURGALIGN HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 2,09 $
Average target price 4,25 $
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Terry M. Rich President, Chief Executive Officer & Director
David B. Lyle Chief Financial Officer
Sheryl L. Conley Non-Executive Chairman
G. Bryan Cornwall Executive VP-Research & Clinical Affairs
Bob Watkins Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
SURGALIGN HOLDINGS, INC.6.53%27
ABBOTT LABORATORIES0.15%191 706
MEDTRONIC PLC6.25%109 846
BECTON, DICKINSON AND COMPANY-0.98%71 584
DEXCOM, INC.-5.76%41 221
HOYA CORPORATION13.14%39 434